Otezla is already approved for moderate to severe plaque psoriasis patients who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis, adults with oral ulcer associated with Behçet’s disease.
The product is approved in more than 50 markets outside the U.S.
The product sales in 2018 were $1.6 billion.
Amgen’s acquisition of Otezla entices us to accumulate AMGN after some robots tried to cause an irrelevant selloff of the stock. Bristol Myers-Squibb (BMY) will definitely benefit from this agreement as the firm is in the process of acquiring Celgene.
The Stock Market Opened Higher Today.
To read more about these firms please run a search from our website by clicking here.
Amgen to Acquire Celgene’s Product Otezla at $13.4 Billion
Amgen Agreement with Celgene for Otezla®
In the News
Amgen (AMGN) entered into an agreement with Celgene (CELG) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities for $13.4 billion in cash.
Amgen cited the benefits of this agreement as follows: